Johnson & Johnson to Invest $1B+ in PA Cell Therapy Facility – Creating 4500+ Jobs

Johnson & Johnson Invests Over $1 Billion in Pennsylvania Cell Therapy Facility

February 18, 2026 – Johnson & Johnson announced today a more than $1 billion investment in a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. The new facility is expected to create more than 4,000 construction jobs and over 500 skilled biomanufacturing positions once fully operational.

The investment, described by the company as uniting “scientific excellence with state-of-the-art manufacturing and strategic investment,” aims to bolster Johnson & Johnson’s U.S. Manufacturing capacity as it develops treatments for cancer, immune-mediated diseases, and neurological disorders. According to Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson, the company has been a “leading innovator in American healthcare for 140 years” and is “honored to continue advancing that legacy in Pennsylvania.”

The facility will utilize cutting-edge cell therapy technologies to produce a portfolio of what the company calls “transformational medicines.” Johnson & Johnson stated it is also committed to investing in training programs to develop a workforce skilled in the advanced technologies shaping the future of medicine.

Pennsylvania Governor Josh Shapiro hailed the investment as a sign of the state’s growing prominence in the life sciences industry. “Just a few years ago we weren’t even on the field – but today we’re competing and winning,” Governor Shapiro said. He credited the state’s first economic development plan in two decades, along with efforts to cut red tape and make strategic investments, for attracting the project.

The project is supported by a $41.5 million state investment, which is expected to create more than 500 new jobs and retain over 5,800 existing positions across Pennsylvania, according to the Governor’s office. The new cell therapy manufacturing facility will be operated by Janssen Biotech, a Johnson & Johnson subsidiary, and will focus on the production of medicines for serious illnesses.

The investment comes as global drugmakers are reportedly seeking to increase their presence in the United States. The timing may also be influenced by concerns over potential tariffs, though this was not directly addressed in Johnson & Johnson’s announcement.

Johnson & Johnson’s decision to expand its U.S. Footprint represents a significant boost to the Pennsylvania economy and underscores the growing importance of cell therapy in the treatment of complex diseases. The company’s commitment to workforce development is also expected to have a positive impact on the region, providing opportunities for skilled workers in the biomanufacturing sector.

The new facility is being constructed in Lower Gwynedd Township, Montgomery County. The company anticipates the facility will support more than 500 skilled biomanufacturing jobs when fully operational.